Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial
- DOI
- 10.1016/j.breast.2026.104903
- Published
- 2026-10
- Container
- The Breast
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.breast.2026.104903,
title = {Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial},
author = {Tejal.D. Durgekar and Shyamili Goutham and Xi Zhang and Elma.Meershoek-Klein Kranenbarg and Badada.Ananthamurthy Savitha and Payal Shrivastava and K.S. Deepti and Naveen Krishnamoorthy and Hein Putter and Manvi Sunder and Erik J. Blok and Cornelis.J.H. van de Velde and Peter.J.K. Kuppen and Manjiri Bakre},
year = {2026},
journal = {The Breast},
doi = {10.1016/j.breast.2026.104903},
url = {https://doi.org/10.1016/j.breast.2026.104903}
}RIS
TY - JOUR TI - Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial AU - Tejal.D. Durgekar AU - Shyamili Goutham AU - Xi Zhang AU - Elma.Meershoek-Klein Kranenbarg AU - Badada.Ananthamurthy Savitha AU - Payal Shrivastava AU - K.S. Deepti AU - Naveen Krishnamoorthy AU - Hein Putter AU - Manvi Sunder AU - Erik J. Blok AU - Cornelis.J.H. van de Velde AU - Peter.J.K. Kuppen AU - Manjiri Bakre PY - 2026 JO - The Breast DO - 10.1016/j.breast.2026.104903 UR - https://doi.org/10.1016/j.breast.2026.104903 ER -
APA
Durgekar, T., Goutham, S., Zhang, X., Kranenbarg, E., Savitha, B., Shrivastava, P., Deepti, K., Krishnamoorthy, N., Putter, H., Sunder, M., Blok, E. J., Velde, C. V. D., Kuppen, P., & Bakre, M. (2026). Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial. The Breast. https://doi.org/10.1016/j.breast.2026.104903
Source records
- crossref · retrieved 2026-09-25T14:19:42.874Z